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Clinical and Immunomodulating Effects of Ketamine in Horses with
Experimental Endotoxemia
Abstract
Background: Ketamine has immunomodulating effects both in vitro and in vivo during
experimental endotoxemia in humans, rodents, and dogs.
Hypothesis: Subanesthetic doses of ketamine will attenuate the clinical and immunologic responses to
experimental endotoxemia in horses.
Animals: Nineteen healthy mares of various breeds.
Methods: Experimental study. Horses were randomized into 2 groups: ketamine-treated horses (KET; n = 9)
and saline-treated horses (SAL; n = 10). Both groups received 30 ng/kg of lipopolysaccharide (LPS,
Escherichia coli, O55:B5) 1 hour after the start of a continuous rate infusion (CRI) of racemic ketamine (KET)
or physiologic saline (SAL). Clinical and hematological responses were documented and plasma
concentrations of tumor necrosis factor-α (TNF-α) and thromboxane B2 (TXB2) were quantified.
Results: All horses safely completed the study. The KET group exhibited transient excitation during the
ketamine loading infusion (P < .05) and 1 hour after discontinuation of administration (P < .05).
Neutrophilic leukocytosis was greater in the KET group 8 and 24 hours after administration of LPS (P < .05).
Minor perturbations of plasma biochemistry results were considered clinically insignificant. Plasma TNF-α
and TXB2 production peaked 1.5 and 1 hours, respectively, after administration of LPS in both groups, but a
significant difference between treatment groups was not demonstrated.
Conclusions and Clinical Importance: A subanesthetic ketamine CRI is well tolerated by horses. A
significant effect on the clinical or immunologic response to LPS administration, as assessed by clinical
observation, hematological parameters, and TNF-α and TXB2production, was not identified in healthy horses
with the subanesthetic dose of racemic ketamine utilized in this study.
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Clinical and Immunomodulat ing Effects of Ketamine in Horses with
Experimental Endotoxemia
C.J. Alcott, B.A. Sponseller, D.M. Wong, J.L. Davis, A.M. Soliman, C. Wang, and W. Hsu
Background: Ketamine has immunomodulating effects both in vitro and in vivo during experimental endotoxemia in
humans, rodents, and dogs.
Hypothesis: Subanesthetic doses of ketamine will attenuate the clinical and immunologic responses to experimental
endotoxemia in horses.
Animals: Nineteen healthy mares of various breeds.
Methods: Experimental study. Horses were randomized into 2 groups: ketamine-treated horses (KET; n 5 9) and saline-
treated horses (SAL; n5 10). Both groups received 30 ng/kg of lipopolysaccharide (LPS, Escherichia coli, O55:B5) 1 hour after
the start of a continuous rate infusion (CRI) of racemic ketamine (KET) or physiologic saline (SAL). Clinical and hematolog-
ical responses were documented and plasma concentrations of tumor necrosis factor-a (TNF-a) and thromboxane B2 (TXB2)
were quantiﬁed.
Results: All horses safely completed the study. The KET group exhibited transient excitation during the ketamine loading
infusion (Po .05) and 1 hour after discontinuation of administration (Po .05). Neutrophilic leukocytosis was greater in the
KET group 8 and 24 hours after administration of LPS (P o .05). Minor perturbations of plasma biochemistry results were
considered clinically insigniﬁcant. Plasma TNF-a and TXB2 production peaked 1.5 and 1 hours, respectively, after adminis-
tration of LPS in both groups, but a signiﬁcant difference between treatment groups was not demonstrated.
Conclusions and Clinical Importance: A subanesthetic ketamine CRI is well tolerated by horses. A signiﬁcant effect on the
clinical or immunologic response to LPS administration, as assessed by clinical observation, hematological parameters, and TNF-a
and TXB2 production, was not identiﬁed in healthy horses with the subanesthetic dose of racemic ketamine utilized in this study.
Key words: Horses; Immunomodulation; Lipopolysaccharide; Subanesthetic ketamine; Thromboxane; Tumor necrosis factor-a.
Endotoxemia is an important cause of morbidityand death in horses with diseases involving Gram-
negative bacteria such as those associated with gastro-
intestinal dysfunction, pleuropneumonia, metritis, and
peritonitis.1–3 Exposure of host cells to lipopolysaccharide
(LPS), or endotoxin, activates multiple inﬂammatory and
immune responses intended to control Gram-negative
infection. However, the activation and ampliﬁcation of
these responses can be excessive and result in detrimental
effects to the host.4 Production of tumor necrosis factor-a
(TNF-a) is one of the earliest indicators of endotoxemia
and contributes directly to the systemic clinical signs ob-
served during periods of endotoxemia in the horse.4 At a
cellular level, TNF-a, activates the arachidonic acid cas-
cade and cyclooxygenase-1 and -2 (COX), resulting in
further production of other proinﬂammatory prostanoids
and eicosanoids, such as thromboxanes, prostacyclins, and
other prostaglandins.1,5
LPS-induced platelet and monocyte activation is a source
of thromboxane production during periods of shock and
endotoxemia in horses, resulting in microcirculatory dys-
function.1,6–8 Thromboxane also represents COX-1 activity.9
Therefore thromboxane and its stable metabolite thrombox-
ane B2 (TXB2) are indicators of inﬂammatory changes that
occur after LPS-induced endotoxemia in the horse.
Nonsteroidal anti-inﬂammatory drugs, polymixin B,
pentoxifylline, plasma, phospholipid emulsions, pirfeni-
done, and E5531 have all been used to treat endotoxemia
in horses.10–14 The target of many of these medications is
decreasing the production of inﬂammatory mediators
such as TNF-a and thromboxane, which may, in turn,
improve clinical status and outcome in endotoxemic horses.
Ketamine is a dissociative anesthetic routinely used in
veterinary medicine. Additionally, ketamine has positive
immunomodulating and anti-inﬂammatory effects dur-
ing periods of experimental endotoxemia and septic
shock in rats.15,16 Speciﬁcally, ketamine down-regulates
nuclear factor kappa B (NFkB) signaling, decreases
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inﬂammatory cytokine production (TNF-a, interleukin-
6 [IL-6]), and suppresses platelet aggregation in mouse,
human, and equine cell lines after exposure to LPS.17–20
Furthermore, in vitro ketamine inhibits COX-2 expres-
sion in rats.21 In dogs, subanesthetic ketamine demon-
strates anti-inﬂammatory properties during periods of
experimental endotoxemia.22,23
Immunomodulating properties of subanesthetic keta-
mine in horses during experimental endotoxemia have
not been investigated in vivo. The potential of ketamine
to attenuate the inﬂammatory and immune responses in
endotoxemic horses is supported by previous reports.18,19
Hence, we hypothesized that a subanesthetic ketamine
continuous rate infusion (CRI) can safely be administered
to conscious horses and attenuate the clinical, inﬂamma-
tory, and immunologic responses in an experimental
model of endotoxemia in healthy horses. Speciﬁcally, we
investigated proinﬂammatory cytokine and prostanoid
production (TNF-a and TXB2) and monitored the clinical
and hematologic changes after LPS administration.
Materials and Methods
Experimental Animals
Nineteen healthy mares (11 Quarter Horse, 3 American Paint
Horse, 2 Thoroughbred, 2 Friesian, 1 Appaloosa) with a mean age
of 7.8 years (range 4–11 years) and mean body weight of 563 kg
(range 505–664kg) were randomly selected from the Iowa State
University teaching herd. All horses were healthy, had no history of
illness or treatments in the last 60 days, were in good body condition
(BCS 6–9), and fed free choice grass/alfalfa hay. Health status of all
horses was based on a complete physical examination, CBC, and
serum biochemistry analysis 24 hours before the study; all parame-
ters were within acceptable reference ranges. Horses were allowed to
acclimatize to the study environment for 24 hours and were fed
grass/alfalfa hay and water ad libitum during the study period.
Horses were divided into 2 randomized groups: saline-treated
horses (SAL) and ketamine-treated horses (KET). The KET group
(n5 9) was administered racemic ketaminea in a step-wise loading in-
fusion followed by a CRI as stated below. The SAL group (n 5 10)
received a similar step-wise loading infusion and CRI of 0.9% saline
with a matched volume to body weight ratio as KET horses. All
horses received LPS (Escherichia coli 055:B5)b 1 hour after initiation
of the loading infusion of ketamine or saline. The investigators were
not blinded to treatment groups. All treatments and procedures were
performed in accordance with the Iowa State University Institutional
Animal Care and Use Committee approved guidelines. All horses
were returned to the teaching herd at the end of the study period.
Sampling
IV jugular cathetersc were placed aseptically, after SC inﬁltration
of 2% lidocaine, into the right and left external jugular veins. All
blood samples were collected via the left jugular catheter while
administration of LPS ketamine, saline, or both occurred via the
right jugular catheter. Venous blood samples for CBC and TXB2
analysis were collected in tubes containing EDTA. Samples con-
taining EDTA were processed within 1 hour for CBC or centrifuged
at 1,000g for 10 minutes at which point the plasma was harvested
and stored at 201C for future TXB2 analysis. Venous blood sam-
ples for ketamine analysis were collected in tubes containing lithium
heparin and centrifuged at 1,000 g for 10 minutes at 201C for col-
lection of the plasma fraction. Heparinized plasma samples were
processed within 1 hour of collection for plasma biochemistry anal-
ysis or stored at 201C for TNF-a quantiﬁcation.
Treatment Groups
KET Group. Nine healthy mares were administered a loading
dose of 0.3% racemic ketamine in 0.9% saline via infusion pumpd in
a step-wise infusion protocol: 4.8, 3.6, 3.0, 2.4mg/kg/h in 10-minute
intervals (Fig 1). At the completion of the 2.4mg/kg/h loading dose,
the ketamine CRI was adjusted to maintain a rate of 1.5mg/kg/h for
320 minutes, for a total infusion period of 360 minutes (6 hours).
The targeted plasma ketamine concentration was 200 ng/mL for 5
hours with an acceptable range of 100–500ng/mL. This dosing
strategy was expected to yield the targeted concentrations.24 One
hour after the initiation of the ketamine loading dose (time 0), 30 ng/
kg LPS (E. coli O55:B5) in 60mL of 0.9% saline was administered
over 30 minutes via an automated infusion pump.12 Clinical re-
sponse to endotoxin administration was assessed by physical
examination and clinical scoring at 1, 0.5, 0, 0.5, 1, 2, 3, 4, 5, 6,
8, 12, and 24 hours. Blood samples were collected at 1, 0, 0.5, 1,
1.5, 2, 3, 5, 8, and 24 hours and at 2, 5, and 24 hours for CBC and
plasma biochemistry analysis, respectively. Serum ketamine con-
centrations were determined at 1, 0, 1, 2, 3, 5, and 8 hours. The
inﬂammatory cytokine response to LPS administration was assessed
via blood TNF-a (1, 0, 0.5, 1, 1.5, 2, 3, 5, and 8 hours) and TXB2
(0, 0.5, 1, 1.5, and 3 hours) concentrations. Collection points were
based on previous work12,25 that indicated peak TNF-a and TXB2
levels would be achieved 1.5 hours after LPS administration and re-
turn to baseline within 3 hours.
SAL Group. Ten healthy mares were administered a loading
dose and CRI of 0.9% saline in identical fashion to the KET group
horses. Horses in both groups received the same volume (mL/kg
body weight) of solution, 0.3% ketamine, or 0.9% saline. Clinical
evaluation and blood sample collection were performed as outlined
above for the KET group horses.
Physical Examinations
Heart rate (HR), respiratory rate (RR), rectal temperature (RT),
and clinical scores were monitored at the time intervals described
0
1
2
3
4
5
6
K
et
am
in
e 
CR
I (m
g/k
g/h
)
Time (min)
LPS
Fig 1. Ketamine step-wise loading infusion starting at time 60
minutes and adjusted every 10 minutes as follows: 4.8, 3.6, 3.0, and
2.4mg/kg/h. The ketamine continuous rate infusion (CRI) was
maintained at 1.5mg/kg/h from time 20 to 300 minutes. Lipo-
polysaccharide (Escherichia coli O55:B5, 1 ng/kg/min30min) was
administered to both groups at time 0 minute.
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above. Clinical scoring was based on a nonblinded subjective assess-
ment by the investigator (C.A.) utilizing a 4-point severity score (0–3).
Horses categorized as: 0—no clinical evidence of abnormal behavior;
1—mild lethargy, restlessness or muscle fasciculations or both; 2—
moderate lethargy, restlessness, muscle fasciculations, inappetance or
hyperesponsiveness or both, without signs of abdominal discomfort;
3—severe clinical evidence of lethargy, restlessness, pawing, sweating,
muscle fasciculations, signs of abdominal discomfort (cramping,
looking at sides, rolling), incoordination, hyperesponsiveness or
nystagmus or both. Objective data (HR, RR, and RT) were not used
to determine clinical scores.
Laboratory Methods
CBC/Plasma Biochemistry Analysis. Analyses were per-
formed by commercial automated analyzers.e,f
TNF-a. Quantiﬁcation was based on previously described ELI-
SA methods.12 Brieﬂy polyclonal antibodyg was incubated with
heparinized plasma samples in a 96-well microtiter plate.h After
washing with phosphate-buffered saline with tween,h equine recom-
binant TNFh was added in standard dilutions to each well. The
optical density was determined at 405 nm after an additional wash
and addition of biotin-labeled polyclonal antibody.h TNF-a activity
was expressed as picograms per milliliter.
TXB2. One milliliter of plasma was injected into the C18 Sep-
Pak column,i which had been preconditioned by washing the col-
umn with 5mL of methanol followed by 5mL of deionized water.
After sample loading, the column was washed with 5mL of deion-
ized water followed by 5mL of high-pressure liquid chroma-
tography grade hexane. TXB2 was eluted from the column with
5mL ethyl acetate containing 1% methanol by gravity. The organic
solvent was removed under a stream of nitrogen and the dried sam-
ple was stored at 201C until assayed. For enzyme immunoassay
(EIA) of TXB2, the sample was dissolved with 1mL of EIA buffer
provided by the manufacturer. The TXB2 concentrations were mea-
sured by an EIA kit.j The range of the standard curve for TXB2 EIA
was 62.5–1,000pg/mL. All assays were performed in duplicate with
the average value between duplicates being reported.
Intra- and interassay variations were o5 and o8%, respectively.
The cross-reactivity with 2,3-dino-TXB2 and 11-dehydro-TXB2 was
30 and 0.07%, respectively.
Ketamine. Ketamine concentrations were determined by ultra-
performance liquid chromatography with mass spectrometry
(UPLC/MS)k by a solid phase extraction technique. A stock solu-
tion of ketamine HCll was prepared by dissolving reference
standard in 100% methanol at a concentration of 1mg/mL. Fur-
ther dilutions were made with 10% methanol in water and those
dilutions were used to spike naı¨ve equine plasma for calibration
curves. Samples and standards were extracted identically by the fol-
lowing method: phosphoric acid (20 mL) was added to 1mL of
plasma before extraction; extraction was carried out using hydro-
philic-lipophilic balance cartridges;m the cartridges were
conditioned with 1mL of methanol followed by 1mL of water;
1mL of sample or standard was then extracted, followed by 1mL of
5% methanol in water. Elution was achieved using 1mL of metha-
nol. The eluent was evaporated to dryness using compressed
nitrogen (17 psi) for 12 minutes at 501C. Standards and samples
were reconstituted with 250mL of mobile phase, placed into ﬁlter
vialsn and loaded onto the UPLC for analysis.
An isocratic elution was performed on a C18 column
o using
0.5mL of sample. The mobile phase consisted of water with 0.2%
acetic acid (70%) and methanol (30%) at a ﬂow rate of 0.5mL/min.
The column was maintained at 401C while samples were kept at 41C
during analysis. Ketamine was monitored in positive electrospray
mode, using ion 238 for quantiﬁcation. The voltages of theMS were
as follows: capillary 4.5 kV, cone 30V, extractor 5V, and RF lens at
0.1V. Source and desolvation temperatures were 1001C and 4001C
with a nitrogen gas ﬂow of 20 and 600L/h, respectively. Vacuum
was maintained at 1.0104mbar.
The area under the curve of the peak was plotted versus the
known standard concentration and linear regression analysis was
performed by standard softwarep to obtain a slope, which was used
to calculate the unknown sample concentration (y5mx1 b). Stan-
dards for ketamine were quantiﬁed from 0.01–0.5mg/mL and were
determined to be linear on each day of analysis with a coefﬁcient of
determination (R2) of 40.99 for each dataset. Limits of detection
and quantiﬁcation of ketamine were determined to be 0.005 and
0.01mg/mL, respectively, during initial method validation. The
mean  SD coefﬁcients of variation at ketamine concentrations of
0.5, 0.1, and 0.01mg/mL were 6.87  7.73%. Average recovery of
ketamine in plasma was 96  15%.
Statistical Analysis
Data collected 1 hour before ketamine or saline administration
(1 hour) were considered resting values, with the exception of
TXB2 in which time 0 was used. Baseline correction was deﬁned as
deducting individual horse-resting values from the corresponding
collected data to account for variances in resting values. All data
were baseline corrected during statistical analyses with the excep-
tion of clinical scores. Log transformation was applied to stabilize
variances of the monocyte count and HR, RR, TNF-a, and TXB2
values. A repeated measures analysis of variance model was used to
analyze each of the quantitative responses listed above. Treatment
group (KET versus control), time, and their interaction were used as
ﬁxed effects, and each horse was the subject of repeated measures.
Degrees of freedom were adjusted by the Kenward-Roger method.
Treatment groups were compared by Student’s t-test at each time
point. The ordinal response of clinical scoring was assessed between
treatment groups via nonparametric Wilcoxon’s sum-rank test at
each time point. Pearson’s correlation coefﬁcients were used to
determine correlation among plasma ketamine concentration,
WBC, and log converted values for TNF-a and TXB2. Spearmen’s
correlation coefﬁcients were used to determine correlation among
clinical score and plasma ketamine concentration, WBC, and log
converted values for TNF-a and TXB2. Statistical analyses were
performed with SASq software. A P-value  .05 (or smaller) was
considered signiﬁcant in this analysis.
Results
Clinical Assessment
All horses safely completed the study and maintained
consciousness. Clinical scores of the SAL group were not
signiﬁcantly changed over time from resting values (time
1 hour), whereas the KET group clinical scores were
increased at 0.5 and 0 hours (Po .05), coinciding with
the ketamine loading infusion period (Fig 2). One horse
within the KET group had a consistently increased clin-
ical score during the ketamine CRI (1 to 5 hours) with a
median score of 1 (SD  1.33), whereas the remaining
horses within the KET group had median scores below
0.5 with 1 horse never exceeding a score of 0. Clinical
scores in the KET group were signiﬁcantly greater than
the SAL group at .5, 0, and 6 hours (P o .05). There
was not a signiﬁcant correlation between plasma keta-
mine concentration and clinical score.
HR increased signiﬁcantly above resting values (time
1 hour) over time in both groups (Table 1). Peak HR
above baseline occurred 2 hours after administration of
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LPS (f-LPS, time 0) in both groups. RR was signiﬁcantly
increased above resting values over time in the KET
group at 6 hours (P o .05) but not in the SAL group.
Peak RR occurred in the SAL group 4 hours and in the
KET group 6 hours f-LPS. RT was signiﬁcantly
increased over time above resting values in both groups
(P o .05) f-LPS. Peak RT occurred 3 hours f-LPS in
both treatment groups. Signiﬁcant differences in HR,
RR, or RT were not identiﬁed between treatment
groups at any time point throughout the study period
(Table 1).
Clinical Pathology
Both groups demonstrated a signiﬁcant leukopenia (P
o .05), neutropenia (P o .05), leukocytosis (P o .05),
and neutrophilia (Po .05) compared with resting values
(time1 hour) over time with a nadir of 1.5 hours (Figs 3
and 4). The KET group had a signiﬁcantly greater leu-
kocyte response characterized by a neutrophilia
(leukocytosis 8 hours, P o .05; neutrophilia 8 and 24
hours, P o .05) f-LPS compared with the SAL group.
Lymphopenia was signiﬁcant (Po .05) over time in both
groups relative to resting values with lymphocytosis
occurring in both groups 24 hours f-LPS (SAL: Po .05,
KET: P o .05). Monocytopenia was signiﬁcant from
resting values over time in the SAL group (Po .05) and
not in the KET group, whereas a signiﬁcant monocytosis
occurred in the KET group 8 hours (P o .05) f-LPS.
There was no signiﬁcant difference between treatment
groups regarding lymphocyte and monocyte counts (Figs
5 and 6). Fibrinogen decreased signiﬁcantly from resting
values over time in the SAL group 5 hours f-LPS (P 5
.05), but was within reported reference intervals. No sig-
niﬁcant difference in ﬁbrinogen concentration was
identiﬁed between groups. Hematocrit was not signiﬁ-
cantly different between groups or from resting values
over time. The administration of ketamine did not have a
signiﬁcant effect on the complete blood count before LPS
administration (time 1 to 0 hours) in the KET group,
nor was there a signiﬁcant difference between treatment
groups during this same time period.
Plasma biochemistry analyses demonstrated minor
perturbations from resting values in both treatment
groups and are summarized in Table 2. The KET group
had a signiﬁcant increase in plasma chloride (5 hours, P
5 .05) and creatinine (5 hours, Po .05) and decrease in
phosphorus (24 hours, P o .05) relative to the SAL
group. Signiﬁcant differences were not demonstrated
between treatment groups at any time point regarding
plasma sodium, potassium, bicarbonate, calcium, mag-
nesium, BUN, glucose, total protein, albumin, AST,
creatine kinase, ALP, GGT, and total bilirubin.
Immunologic Variables
Plasma TNF-a. TNF-a production was signiﬁcantly in-
creased above resting values (time1 hour) over time in the
SAL group at 1 and 1.5 hours (Po .05), and in the KET
group at 1, 1.5, 2, 3, and 8 hours (Po .05) f-LPS (Fig 7).
TNF-a production was not signiﬁcantly different between
treatment groups, although the SAL group demonstrated a
trend of lower production versus the KET group at 1 hour
(P5 .06). Peak TNF-a production occurred at 1.5 hours in
both treatment groups (SAL: 2,211  2,162pg/mL, KET:
3,404  2,633pg/mL) although these values were not sig-
niﬁcantly different (P5 .08).
Plasma TXB2. Both groups demonstrated signiﬁcant
TXB2 production from resting values (time 0) over time
(SAL: 1 hour, P o .0001; KET: 1 hour, P o .05) f-LPS
(Fig 8). However, no signiﬁcant difference was observed
between treatment groups at any time point during the
study period. TXB2 production was not determined before
time 0, which limits interpreting the effects of the ketamine
CRI alone; however, values obtained from both treat-
ment groups at time 0 were not signiﬁcantly different
(SAL: 117.5  75.2 pg/mL, KET: 159.4  114pg/mL,
P5 .60).
Plasma Ketamine
Plasma ketamine concentration obtained throughout
the study period of the KET group was 248 95.1 ng/mL
(mean, SD, Fig 9). The ketamine loading infusion
resulted in a plasma ketamine concentration at time 0
hour of 238 ng/mL (mean, range 137–357 ng/mL).
Plasma ketamine concentration peaked 5 hours f-LPS
(mean 286, range 114–546 ng/mL) and rapidly declined
after discontinuation of the ketamine CRI at 5 hours.
Although 1 horse had plasma ketamine levels4500ng/mL,
no correlation among clinical score, WBC, TNF-a or TXB2
could be made. Three hours after discontinuation of the
ketamine CRI (8 hours f-LPS) mean plasma ketamine
concentration was 21.7  16.3 ng/mL.
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Fig 2. Clinical scores for ketamine-treated horses (KET) group
(black diamond) and saline-treated horses (SAL) group (square)
horses were based on nonblinded assessment and assigned a
severity score 0–3. Horses categorized as 0—showed no clinical ev-
idence of abnormal behavior; 1—had mild lethargy, restlessness or
muscle fasciculations or both; 2—had moderate lethargy, restless-
ness, muscle fasciculations, inappetance or hyperesponsiveness
or both, without signs of abdominal discomfort; 3—had severe clin-
ical evidence of lethargy, restlessness, pawing, sweating, muscle
fasciculations, abdominal discomfort, incoordination, hyperespon-
siveness or nystagmus or both. Signiﬁcant difference between
groups (Po .05). Mean  SD.
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Discussion
This study documents the immunologic response to
LPS in healthy horses receiving a subanesthetic dose of
ketamine as a CRI. All horses completed the study, and
those in the KET group were safely administered a sub-
anesthetic ketamine CRI of 1.5mg/kg/h during
experimental endotoxemia. Both KET and SAL treat-
ment groups demonstrated mild lethargy, tachycardia,
tachypnea, fever, and a neutropenic leukopenia consis-
tent with previous reports of experimental endotoxemia
induction by administration of 30 ng/kg LPS (E. coli
O55:B5).13,26 Horses in the KET group had plasma keta-
mine concentrations above 100 ng/mL throughout the
5-hour study period consistent with our target concen-
tration. The subanesthetic dose of ketamine utilized in
this study did not appreciably attenuate the clinical and
immunologic response to endotoxin administration
in healthy horses when compared with those receiving a
solution of 0.9% saline (SAL group).
The exact immunomodulating dose of subanesthetic
ketamine in the horse is unknown. In vitro work indicates
that ketamine concentrations 4100ng/mL signiﬁcantly
reduced the production of LPS-induced TNF-a and IL-6
in equine macrophages and ketamine’s dose-dependent in-
hibition of LPS-induced proinﬂammatory cytokines is well
documented in other species.16,17,27 The typical ketamine
anesthetic induction dose used in horses (2.2mg/kg) can
result in peak plasma levels 45,000ng/mL, with CNS
dissociative effects occurring at 800ng/mL and anesthetic
recovery beginning when plasma levels decline below
1,000ng/mL.19,28,29 In the this study, the KET group
attained plasma ketamine concentrations 4200ng/mL
throughout the study period with 1 horse exceeding
500ng/mL at 5 hours f-LPS. The staged loading infusion
protocol (Fig 1) resulted in plasma ketamine concentra-
tions above the targeted 100ng/mL (mean 238 67ng/mL)
within 60 minutes and through the subsequent 4 hours
within the hypothesized therapeutic range.
Clinical assessment of horses in both treatment groups
was based on nonblinded clinical scoring and its inter-
pretation should be viewed with caution. The clinical
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Fig 4. Neutrophil count of ketamine-treated horses (KET) group
(black diamond) and saline-treated horses (SAL) group (square)
horses. Ketamine and saline continuous rate infusion (CRIs) were
initiated at 1 hour and continued to 5 hours. Lipopolysaccharide
(LPS) (055:B5, 30 ng/kg) was administered over 30 minutes at time 0
hour to both group. Signiﬁcant (P o .05) difference between
groups after LPS administration. Mean  SD.
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Fig 3. White blood cell count of ketamine-treated horses (KET)
group (black diamond) and saline-treated horses (SAL) group
(square) horses. Ketamine and saline continuous rate infusion
(CRIs) were initiated at 1 hour and continued to 5 hours. Lip-
opolysaccharide (LPS) (055:B5, 30 ng/kg) was administered over 30
minutes at time 0 hour to both group. Signiﬁcant (Po .05) differ-
ence between groups after LPS administration. Mean  SD
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response to a subanesthetic ketamine CRI is well docu-
mented, so the objective of this study was to monitor for
unanticipated clinical changes warranting immediate dis-
continuation of treatment.30,31 None were observed. The
limited sensitivity of the clinical scoring scheme likely
underrepresented some clinical features as most horses in
the SAL group demonstrated varying degrees of mild
lethargy consistent with the previously mentioned mod-
els of experimental endotoxemia.12,13,15 The increased
clinical scores in the KET group are consistent with ad-
ministration of the ketamine loading infusion (time1 to
0 hours) and were expected given the rapid nature of the
infusion. As clinical scores in the KET group at time 0
were increased above baseline, it is difﬁcult to interpret
the effects of LPS administration alone in this treatment
group. Unexpectedly, clinical scores were increased in the
KET group 6 hours f-LPS and were characterized
by transient excitation and hyperesponsiveness. Rapid
accumulation of ketamine and its metabolites, norketa-
Table 2. MeanSD serum biochemistry analyses of
KET group and SAL group horses.
Time (hours) 1 2 5 24
Sodium (mEq/L)
Saline 138 (2) 139 (2) 139 (2) 139 (2)
Ketamine 139 (1) 141 (2)w 143 (3)w 139 (3)
Potassium (mEq/L)
Saline 3.4 (0.3) 3.3 (0.4) 3.1 (0.4) 3.04 (0.4)
Ketamine 3.2 (0.6) 3.1 (0.3) 3 (0.4) 3.03 (0.7)
Chloride (mEq/L)
Saline 99 (2) 102 (1)w 102 (2)w 100 (2)
Ketamine 100 (2) 104 (1)w 105 (1)w 101 (2)
Bicarbonate (mEq/L)
Saline 29 (2) 27 (2)w 26 (2)w 28 (2)
Ketamine 29 (2) 26 (2)w 26 (1)w 27 (2)w
Calcium (mg/dL)
Saline 12 (0.6) 12 (0.6) 12 (0.7) 12 (0.4)
Ketamine 12 (0.5) 12 (0.5) 12 (0.7) 12 (0.4)
Phosphorus (mg/dL)
Saline 6.2 (11) 3.1 (0.8) 2.4 (1) 2.2 (0.6)w
Ketamine 3.2 (0.8) 3.3 (0.8) 2.1 (0.7)w 1.8 (0.5)w
Magnesium (mg/dL)
Saline 1.8 (0.2) 1.5 (0.2)w 1.4 (0.2)w 1.7 (0.2)
Ketamine 1.7 (0.2) 1.5 (0.1)w 1.5 (0.1)w 1.6 (0.2)
BUN (mg/dL)
Saline 21 (2) 19 (3) 18 (3)w 17 (2)w
Ketamine 21 (2) 20 (3) 19 (3)w 18 (3)w
Creatinine (mg/dL)
Saline 1.03 (0.1) 1.2 (0.2)w 1.1 (0.2) 1.1 (0.1)w
Ketamine 1.09 (0.1) 1.3 (0.2)w 1.4 (0.3)w 1.1 (0.2)
Glucose (mg/dL)
Saline 108 (11) 107 (5) 110 (8) 121 (21)w
Ketamine 107 (11) 112 (20) 105 (19) 123 (27)w
Total protein (gm/dL)
Saline 6.9 (0.4) 7.3 (0.7)w 7.1 (0.6)w 7.1 (0.5)
Ketamine 6.9 (0.4) 7.4 (0.4)w 7.2 (0.3)w 7.2 (0.5)w
Albumin (gm/dL)
Saline 3.2 (0.2) 3.4 (0.3)w 3.3 (0.2)w 3.2 (0.2)
Ketamine 3.1 (0.2) 3.3 (0.2)w 3.2 (0.2)w 3.1 (0.2)
AST (IU/L)
Saline 360 (40) 404 (61) 403 (45) 367 (45)
Ketamine 361 (49) 446 (111)w 426 (84)w 378 (71)
Creatine kinase (IU/L)
Saline 349 (145) 349 (97) 317 (88)w 395 (146)
Ketamine 315 (57) 310 (41) 267 (42) 287 (66)
ALP (IU/L)
Saline 162 (30) 232 (41)w 240 (31)w 232 (43)w
Ketamine 181 (31) 274 (68)w 305 (55)w 253 (40)w
GGT (IU/L)
Saline 19 (5) 22 (8)w 21 (9)w 21 (7)w
Ketamine 19 (4) 22 (5)w 22 (4)w 21 (3)w
Total bilirubin (mg/dL)
Saline 0.9 (0.3) 1.2 (0.2)w 1.3 (0.3)w 1.5 (0.6)w
Ketamine 0.8 (0.2) 1.2 (0.3)w 1.3 (0.4)w 1.4 (0.5)w
Ketamine and saline CRIs were initiated at 1 hour and continued
to 5 hours. LPS (055:B5, 30 ng/kg) was administered over 30 min-
utes beginning at time 0 hour to both groups.
CRI, continuous rate infusion; KET, ketamine-treated horses;
LPS, lipopolysaccharide; SAL, saline-treated horses.
Signiﬁcant (Po .05) difference from the saline group.
wSigniﬁcant change from resting values.
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Fig 7. Plasma tumor necrosis factor-a (TNF-a) production in sa-
line-treated horses (SAL) (square) and ketamine-treated horses
(KET) (black diamond) groups. See Figure 3 for further details.
No signiﬁcant (P o .05) difference was determined between treat-
ment groups. wSigniﬁcant (Po .05) difference from baseline in the
SAL group. zSigniﬁcant (P o .05) difference from baseline in the
KET group. Mean  SD.
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Fig 8. Plasma thromboxane B2 production in saline-treated horses
(SAL) (square) and ketamine-treated horses (KET) (black dia-
mond) treatment groups. See description in Figure 3. No signiﬁ-
cant difference was demonstrated between treatment groups. wSig-
niﬁcant (P o .0001) increase above baseline in both treatment
groups. Mean  SD.
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mine and hydroxynorketamine, occurs after loading
boluses/infusions, of which the inﬂuence on CNS stimu-
lation, immune modulation, or analgesia in the conscious
horse is still unclear.24,32 It is unknown if ketamine’s
CNS stimulatory effects potentially masked any attenu-
ation of the clinical response in this study as a study
group receiving a ketamine CRI and not challenged with
LPS was not included.
Previous reports evaluating the pharmacokinetic and
pharmacodynamic properties of subanesthetic ketamine
infusions indicated that plasma ketamine concentration
can be maintained in the conscious horse with minimal
behavioral responses.24,31 Administration of an a-2
adrenoceptor agonist, synthetic opioid, or both before
the ketamine loading phase would likely have negated
the signiﬁcantly higher clinical scores in the KET group,
given long-standing evidence that ketamine’s use without
prior sedation results in signiﬁcant CNS stimulation in
horses, but was not utilized in this study to avoid seda-
tion and potentially slowing the distribution and hepatic
metabolism of ketamine. Alteration of the loading phase
to allow more time to acclimatize to abrupt changes in
ketamine may have lessened the observed CNS stimula-
tion in the KET group horses, but it is unclear what
implications this may have on the metabolism or
immunomodulating properties of ketamine.
The tachycardia and fever documented in the SAL
group is consistent with previous reports using similar
LPS dosing protocols that demonstrated peak tachycardia,
tachypnea, and RT occurring 2–3 hours after LPS admin-
istration.12,25 In the present study, tachycardia and
tachypnea after LPS infusion were not signiﬁcantly differ-
ent between treatment groups, although the KET group
had an increased HR above baseline for 6 hours longer
than the SAL group and an increased RT 1.5 hours earlier
than the SAL group. Peak tachypnea was not signiﬁcantly
above resting values in the SAL group and delayed 1 hour
compared with previous reports.26 The reason for this is
uncertain. A subanesthetic ketamine CRI of 0.8mg/kg/h
had little effect on baseline physiologic parameters beyond
the initial IV bolus.31 Proposed reasons for this, in our
study relative to other studies, include variances in LPS
concentration or content, concurrent IV ﬂuid administra-
tion, and LPS administration technique. This study
suggests that ketamine had little inﬂuence attenuating the
cardiorespiratory response to experimental endotoxemia.
Administration of LPS to horses consistently produces a
leukopenia followed by a rebound leukocytosis, typically
characterized by neutropenia followed by neutrophilia,
along with proinﬂammatory cytokine production.1,12,25
This study demonstrated a similar neutropenic leukopenia
with a nadir 1.5 hours after LPS-infusion. However, the
subsequent neutrophilic leukocytosis was earlier (5 versus
8 hours) and signiﬁcantly greater in the KET group
(leukocytosis at 8 hours and neutrophilia at 8 and 24
hours) compared with the SAL group. The effect of sub-
anesthetic ketamine on equine leukocyte function,
speciﬁcally neutrophils, has not been studied in the horse
but has been explored in humans where ketamine demon-
strated anti-inﬂammatory effects via inhibition of neutrophil
adhesion molecule expression in vitro.26,33 Interestingly in
this study, the anticipated leukocytosis and neutrophilia that
commonly occur in healthy horses after LPS administration
were signiﬁcantly ampliﬁed in theKETgroup, whichmay be
a consequence of attenuated adhesion molecule expression.
Although lymphocyte and monocyte counts were not
signiﬁcantly different between groups, changes from base-
line within the SAL group demonstrated an earlier
lymphopenia and monocytopenia compared with the KET
group. A recent report in dogs indicates that subanesthetic
ketamine did not alter leukocyte response to LPS.23 The
clinical impact of the leukocyte response observed in this
study during periods of endotoxemia is unclear.
In this study, a signiﬁcant effect of subanesthetic keta-
mine on CBC ﬁndings before LPS administration (time
1 to 0 hours) was not observed, suggesting that keta-
mine did not signiﬁcantly inﬂuence the CBC until after
the LPS infusion. This should be interpreted with caution
as plasma ketamine levels were not determined until 1
hour after beginning the ketamine loading infusion
(Fig 9), and although the loading infusion attained a
rapid plasma ketamine concentration, it is unknown if
this was within the hypothesized therapeutic range. Fur-
ther in vivo studies evaluating ketamine’s impact on
leukocyte function at subanesthetic concentrations may
provide insight for these ﬁndings.Minor perturbations of
the plasma biochemistry results were observed from
baseline in both treatment groups as summarized in
Table 2, but were considered clinically insigniﬁcant.
Subanesthetic ketamine did not attenuate the LPS-induced
production of TNF-a compared with control horses in
this study. Average resting plasma TNF-a concentration
varied widely in both treatment groups, suggesting vari-
ability in methods used to quantitate TNF-a (ELISA), a
problem in study design or subclinical inﬂammation in
the study subjects (Fig 7). When resting values were
deducted from subsequent collection times, no signiﬁ-
cant difference between treatment groups was identiﬁed,
although TNF-a production in the KET group remained
increased above resting values for a longer duration than
the SAL group. Peak TNF-a production occurred 1.5
hours after LPS administration, consistent with previous
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Fig 9. Plasma ketamine concentration of the ketamine-treated
horses (KET) group. The KET group received a ketamine loading
infusion as descried in Figure 1. Mean plasma ketamine concentra-
tion from 0 to 5 hours was 248, 95.1 ng/mL. Mean  SD.
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reports and suggesting the dose of LPS utilized was ad-
equate.12,13,26 TNF-a is considered one of the earliest
markers of inﬂammatory cytokine response during peri-
ods of endotoxemia and is a common parameter used to
objectively assess endotoxemia in the horse.34 In vitro
evidence has supported ketamine’s role in attenuating
cellular proinﬂammatory cytokine gene induction,
via NFkB inhibition, after LPS challenge at various
doses (0.05–70mg/kg) and infusions (5–20mg/
kg/h).16,19,21,27,35–37 Rodent and canine in vivo models
have documented the anti-inﬂammatory effects of sub-
anesthetic ketamine via inhibition of proinﬂammatory
cytokine production during experimental end-
otoxemia.15,23,36,38 In contrast to previous ﬁndings in
species other than the horse, subanesthetic ketamine did
not diminish the inﬂammatory response to LPS as
assessed by TNF-a production in this study.
Several factors may have been responsible for the
observed difference between studies. The higher keta-
mine CRI used in this study is greater than that
previously reported and some reports did not determine
plasma ketamine concentrations, nor did they explore
experimental models of endotoxemia in the horse.28,31
Ketamine’s immunomodulation is speculated to be dose
related with moderate doses correlating with greater pro-
inﬂammatory cytokine reduction when compared with
higher doses.16,17,26,39 It is possible that a lower ketamine
CRI might have improved immunomodulation than the
one chosen for this study. Pharmacokinetic principles of
an IV bolus versus a stepwise CRI loading infusion strat-
egy are additional variables that might account for the
difference observed between studies. Individual horse
variation as related to genetics, metabolism of ketamine,
and sensitivity to LPS might have inﬂuenced our results
as well. A cross-over study design would ideally diminish
the inﬂuence of these variables, with LPS tolerance con-
sidered a further confounding factor.40
Plasma TXB2 concentrations were not altered by the
administration of subanesthetic ketamine in this study.
Plasma TXB2 samples were not determined before keta-
mine administration (time 1), so the effects of ketamine
alone are unknown, although no signiﬁcant difference
was determined between treatment groups before LPS
administration. What role subanesthetic ketamine plays
in modulating COX activity and thrombocyte activation
during experimental endotoxemia has not been studied in
the horse. Ketamine has shown signiﬁcant gastrointestinal
protective effects through inhibition of COX-2 in rats
which we hypothesized would be evidenced in this study
by a reduction in TXB2 production.
21,27 The addition of
a COX-inhibitor to EDTA blood collection tubes has been
used in previous reports to limit further platelet COX
activity and was not performed in this study. This poten-
tially inﬂuenced our TXB2 results, but given that both
treatment group’s sample collection and processing tech-
niques were similar, the implications were likely minimized.
In conclusion, the subanesthetic CRI of ketamine used
in this study had minimal adverse effects and negligible
beneﬁcial effects regarding ketamine’s ability to attenu-
ate the immune response to endotoxin administration in
healthy horses.
Footnotes
aKetamine HCl Inj., Ketaset, Fort Dodge Animal Health, Fort
Dodge, IA
b Sigma-Aldrich, St Louis, MO
cAngiocath 14G, 5.25 in., BectonDickinson Infusion Therapy Systems
Inc, Sandy, UT
dMicro-MacroXLFluid Pump, Abbott Laboratories, North Chicago,
IL
e Siemens (Bayer) Advia 120, Seimens Healthcare Diagnostics,
Deerﬁeld, IL
fRoche Hitachi 912, Roche Diagnostics Corporations, Indianapolis,
IN
gThermo Fisher Scientiﬁc (Endogen), Rockford, IL
hMediatech Inc, Manassas, VA
iC18 Sep-Pak, Waters Corporation, Milford, MA
jOxford Biomedical Research, Oxford, MI
kWaters AcquityUPLC andEMD1000MSwith Empower 2 software,
Waters Corporation
lUnited States Pharmacopeia, Rockville, MD
mOasis-HLB (1mL), Waters Corporation
nMini-UniPrep 0.45mm PTFE, Whatman Inc, Clifton, NJ
oAcquity UPLC BEH, 1.050mm, 1.7mm pore size, Waters Corpora-
tion
pMicrosoft Excel, Microsoft Corp, Seattle, WA
q SAS Institute Inc, SAS Version 9.1.3, Cary, NC
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